Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients
- 1 March 2003
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 41 (3) , S108-S111
- https://doi.org/10.1053/ajkd.2003.50097
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 2000
- Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidismKidney International, 1997
- Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.Journal of Clinical Investigation, 1993
- The mechanism for the disparate actions of calcitriol and 22- oxacalcitriol in the intestineEndocrinology, 1993
- Intermittent high-dose oral 1,25-dihydroxyvitaimin D3 for secondary hyperparathyroidism in hemodialysis patientsJournal of Bone and Mineral Metabolism, 1991
- The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.Journal of Clinical Investigation, 1989
- Synthetic studies of vitamin D3 analogues. VIII Synthesis of 22-oxavitamin D3 analogues.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Journal of Clinical Investigation, 1984